首页> Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation> Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia.

Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia.

导出原文传递

翻译打印收藏纠错

第一作者： Areej,El-Jawahri

第一单位： Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, Massachusetts.

作者： Areej,El-Jawahri ^[1] ; Shuli,Li ^[2] ; Karen K,Ballen ^[1] ; Corey,Cutler ^[3] ; Bimalangshu R,Dey ^[1] ; Jessica,Driscoll ^[1] ; Chrisa,Hunnewell ^[1] ; Vincent T,Ho ^[3] ; Steven L,McAfee ^[1] ; Cathleen,Poliquin ^[1] ; Meredith,Saylor ^[1] ; Robert J,Soiffer ^[3] ; Thomas R,Spitzer ^[1] ; Edwin,Alyea ^[3] ; Yi-Bin,Chen ^[4]

作者单位： Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, Massachusetts. ^[1] Division of Computational Biology and Biostatistics, Dana-Farber Cancer Institute, Boston, Massachusetts. ^[2] Division of Hematological Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts. ^[3] Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: ychen6@partners.org. ^[4]

关键词 Acute leukemia Allogeneic transplant Busulfan/clofarabine